{
  "abstract": "Background and Importance Oral antineoplastic agents used in non-small-cell lung cancer (NSCLC), particularly vascular endothelial growth factor (VEGF) inhibitors and RAF/MEK pathway inhibitors, are associated with significant cardiovascular risks. The European Cardio-Oncology Guidelines recommend assessing baseline cardiovascular risk using the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) tool and monitoring the QT interval before and during treatment.Aim and Objectives To assess baseline cardiovascular risk in patients with NSCLC initiating treatment with oral antineoplastic agents and to determine the incidence of cardiovascular adverse events during therapy.Material and Methods A retrospective observational study was conducted at a quaternary-care hospital, including patients with NSCLC who initiated treatment with oral antineoplastic agents between July and December 2023, with follow-up until February 2025. Baseline clinical variables were collected (age, sex, cardiovascular risk factors [CVRFs], and cardiovascular history), along with treatment data and associated cardiovascular adverse events. Patients receiving VEGF or RAF/MEK inhibitors were stratified using the HFA-ICOS tool. The risk of QT interval prolongation associated with oncologic treatment was also assessed and considered moderate to high when other QT-prolonging drugs were co-administered.Results A total of 44 patients (43% female) were included, with a median age of 74.5 years. The most frequently prescribed therapies were osimertinib (n=24), alectinib (n=9), and nintedanib (n=5). At baseline, 84% presented with at least one CVRF, and 27% had a history of cardiovascular disease. Among the 6 patients treated with VEGF or RAF/MEK inhibitors, 3 had high cardiovascular risk and one had moderate risk. Twenty-eight patients received antineoplastic drugs associated with QT prolongation, of whom 8 were classified as having moderate to high risk. After a median follow-up of 22.3 months, 8 patients (18%) developed cardiovascular (n=6) or thromboembolic (n=2) events leading to temporary treatment interruption, although permanent discontinuation was not required. All but one of these patients had CVRFs and/or a cardiovascular history.Conclusion and Relevance Patients with NSCLC treated with oral antineoplastic agents exhibit a high baseline cardiovascular risk, which contributes to an increased incidence of cardiovascular adverse events during cancer treatment. Therefore, close clinical monitoring throughout oncologic therapy is warranted.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "University Hospital of Salamanca, Department of Pharmacy, Salamanca, Spain"
      ],
      "name": "L Lorenzo Vidal"
    },
    {
      "affiliations": [
        "University Hospital of Salamanca, Department of Pharmacy, Salamanca, Spain"
      ],
      "name": "I García París"
    },
    {
      "affiliations": [
        "University Hospital of Salamanca, Department of Pharmacy, Salamanca, Spain"
      ],
      "name": "B Vicente González"
    },
    {
      "affiliations": [
        "University Hospital of Salamanca, Department of Pharmacy, Salamanca, Spain"
      ],
      "name": "MP Valverde Merino"
    },
    {
      "affiliations": [
        "University Hospital of Salamanca, Department of Cardiology, Salamanca, Spain"
      ],
      "name": "A Martín García"
    },
    {
      "affiliations": [
        "University Hospital of Salamanca, Department of Pharmacy, Salamanca, Spain"
      ],
      "name": "N Roso Jiménez"
    },
    {
      "affiliations": [
        "University Hospital of Salamanca, Department of Pharmacy, Salamanca, Spain"
      ],
      "name": "MJ Otero López"
    }
  ],
  "title": "5PSQ-141 Risk assessment and incidence of cardiovascular adverse events associated with oral antineoplastic agents in patients with non-small-cell lung cancer",
  "uid": "32d5bf6e-9591-5556-a028-0706640e8b1f"
}